Introduction
============

Regional and voxel-based semi-quantitative image analysis methods in Alzheimer's Disease (AD) research require normalization of positron emission tomography (PET) images before data analysis. Most amyloid-PET (Aβ-PET) studies in AD use cerebellum as the reference region,[@b1-cia-12-2077]--[@b4-cia-12-2077] however, recent research has found variabilities associated with the cerebellar normalization of amyloid PET images.[@b5-cia-12-2077]--[@b8-cia-12-2077] White matter (WM) can be used for Aβ-PET normalization to reduce longitudinal variability,[@b5-cia-12-2077] increase association to clinical decline[@b7-cia-12-2077] and cerebrospinal fluid levels of Aβ~1--42~[@b8-cia-12-2077] as well enhance discrimination power between subject groups.[@b6-cia-12-2077] However, other recent studies have found impaired amyloid PET radiotracer uptake in damaged areas of WM.[@b9-cia-12-2077] WM injury is common in aging and dementia.[@b10-cia-12-2077]--[@b13-cia-12-2077] Therefore, the utility of WM as a reference region may depend on its structural and functional integrity, which can vary among individual subjects.

Based on these findings, we have identified that the amyloid PET normalization process poses a critical challenge for semi-quantitative PET studies in AD. In this work, we evaluate a different semi-quantitative PET approach that does not require the intensity normalization of Aβ-PET activity to a reference region activity. This method is based on Haralick features (HFs) that can be calculated from the Gray Level Co-occurrence Matrices (GLCMs) of Aβ-PET images to provide a statistical description of the spatial characteristics of amyloid PET.[@b14-cia-12-2077] The objective of this study is to determine whether higher-order texture-based features derived from the GLCMs of \[^18^F\]-Florbetapir-PET images can identify statistically and clinically significant differences between subject groups without using a reference region for PET intensity normalization.

Methods
=======

Alzheimer's disease neuroimaging initiative
-------------------------------------------

The data presented in this study were acquired from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD.

Subjects
--------

The key eligibility criteria of ADNI subject recruitment are available on the ADNI website (<http://www.adni-info.org>). Briefly, enrolled ADNI subjects were between the ages of 55 and 90, had a study partner able to provide an independent evaluation of functioning, and spoke either English or Spanish. All subjects gave written, informed consent before participation through their local Institutional Review Board. All images and metadata for 30 subjects (17 male, 13 female) were acquired from the ADNI database. Selected subjects for this study had undergone longitudinal \[^18^F\]-florbetapir PET scans with concurrent T1-weighted MRIs at baseline and 24-month follow-up. In addition, scores from the neuropsychological assessment Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)[@b15-cia-12-2077] were collected and time-matched to the nearest Aβ-PET acquisition. [Table 1](#t1-cia-12-2077){ref-type="table"} illustrates the demographic and clinical data for selected subjects. The 30 subjects were stratified three ways: by clinical diagnosis (15 normal versus 15 MCI), by APOE e4 allele carrier status (14 non-carriers versus 16 carriers), and by ADAS-Cog score defined as positive by a threshold ≥9 at baseline or follow-up (16 negative versus 14 positive).

\[^18^F\]-florbetapir PET data acquisition
------------------------------------------

All participating sites acquired the \[^18^F\]-florbetapir[@b16-cia-12-2077] PET imaging according to standardized ADNI protocols (<http://adni.loni.usc.edu/methods/pet-analysis/pre-processing/>). Serial PET images for our study were acquired at 13 different centers, and the data were obtained following the dynamic protocol of and preprocessed by ADNI. Dynamic scans were 30-min 6-frame scans acquired 30--60 min after injection. All frames were coregistered to the first frame, summed, and averaged to create a single image volume.

\[^18^F\]-florbetapir PET pre-processing
----------------------------------------

We employed SPM12 (Wellcome Department of Cognitive Neurology) for image pre-processing. The gray matter fractions of 7 anatomic regions were extracted and utilized for ROI analysis: Combined precuneus/posterior cingulate cortex (PCC), left & right frontal lobes (LFL & RFL), left & right parietal lobes (LPL & RPL), left & right temporal lobes (LTL & RTL), and cerebellum for reference region normalization. For each subject, baseline T1-weighted MR image volumes defined the anatomical ROIs in native space using a maximum probability tissue labels derived from the Medical Image Computing and Computer Assisted Interventions Conference 2012 Grand Challenge and Workshop on Multi-Atlas Labeling and provided by Neuromorphometrics, Inc.[@b17-cia-12-2077]--[@b19-cia-12-2077]

Gray level co-occurrence matrix
-------------------------------

The GLCM texture analysis is a method for evaluating higher-order statistical methods in two-dimensional (2D) images. First-order statistics metrics from histograms evaluate only pixel intensities, while GLCM assesses their spatial associations. To generate the GLCM, pixel intensities within 2D images were first discretized. The GLCM was then calculated by tabulating the occurrences of a combination of pixel values between a reference and neighboring pixels for a particular distance and direction.

We used the graycomatrix() function in MATLAB (The MathWorks, Inc., Natick, Massachusetts, USA) to generate all GLCMs. The GLCM was calculated by specifying an offset or displacement vector and counting all pairs of voxels separated by this offset having intensity levels *i* and *j*. By default, the graycomatrix function in MATLAB calculates the GLCM based on the horizontal proximity of the pixels: (0 1). That is the pixel next to the pixel of interest on the same row. However, other voxel spatial relationships can be specified by using the "Offsets" parameter as input. This approach allows for multiple GLCMs with different directions and distances to be generated from a single image. [Figure 1](#f1-cia-12-2077){ref-type="fig"} highlights this process for creating representative GLCMs from a sample image. For each axial slice, 34 GLCMs were calculated for different offsets ([Figure 1A](#f1-cia-12-2077){ref-type="fig"}). Then, an average GLCM (GLCM_avg) was calculated from these individual GLCMs. The HFs were calculated from each GLCM_avg, and then the features were averaged over multiple axial slices. The calculation of the GLCM was performed in 2D mode because the graycomatrix() function requires 2D images.

Haralick features (HFs)
-----------------------

Following six HFs[@b20-cia-12-2077],[@b21-cia-12-2077] were calculated from the GLCM_avg matrices: $$\text{Contrast} = {\sum_{i,j}{\left| {i - j} \right|^{2} \times p\left( {i,j} \right)}}$$ $$\begin{array}{l}
{\text{Correlation} = {\sum_{i,j}\frac{\left( {i - \mu_{i}} \right)\left( {j - \mu_{j}} \right)p\left( {i,j} \right)}{\sigma_{i}\sigma_{j}}};} \\
{\mspace{45mu}\mu_{i} = {\sum_{i}{i \times p\left( {i,j} \right)}};} \\
{\mspace{45mu}\sigma_{i} = \sqrt{\sum_{i}{\left( {i - \mu_{i}} \right)^{2} \times p\left( {i,j} \right)}}} \\
\end{array}$$ $$\text{Dissimilarity} = {\sum_{i,j}{\left| {i - j} \right| \times p\left( {i,j} \right)}}$$ $$\text{Energy} = {\sum_{i,j}{p\left( {i,j} \right)^{2}}}$$ $$\text{Entropy} = - {\sum_{i,j}{p\left( {i,j} \right) \times \text{In}\ p\left( {i,j} \right) + \zeta;\zeta = 10^{- 7}}}$$ $$\text{Homogeneity} = {\sum_{i,j}{\frac{1}{1 + \left| {i - j} \right|} \times p\left( {i,j} \right)}}$$where *i* and *j* are the pixel indices and *p*(*i, j*) represents the GLCM pixel intensities. Briefly describing the HFs, Contrast measures the local variations in the GLCM. Correlation measures the linear dependence of the pixel intensity related to its position in the image. Dissimilarity is akin to Contrast with measuring local variations, however, it has a linear dependent off-diagonal of the GLCM. Energy is associated with local homogeneity in the image. Entropy, similar to how it is defined in physics, measures the spatial disorder in the GLCM. Finally, Homogeneity measures how similar the pixel intensities of the GLCM are, and thus, is akin to a measure of uniformity. It is our hypothesis that HFs may be sensitive to changes in spatial distribution and amyloid activity among different subject groups.

For this study, GLCMs were generated from the largest five axial slices through the PCC, LFL, RFL, LPL, RPL, LTL, and RTL. Before generating the GLCM, each axial slice was discretized into 128 intensity bins. For each slice, GLCMs were generated for each distance between 1 and 4 pixels at angles between 0 and 165 degrees. The average of these GLCMs was used to calculate HFs. As a standard method for comparison, the semi-quantitative regional SUVR values were calculated by normalizing the images to the cerebellar activity.

Statistical analysis
--------------------

Statistical testing was performed to determine if the SUVR measurements and the selected HFs provide significant differences between stratified groups (normal versus MCI; APOE-ε4 non-carriers versus carriers; ADAS-Cog negative versus positive) at baseline and 24-month follow-up for each ROI structure. Unpaired, nonparametric Wilcoxon statistical tests were employed to compare HFs, while unpaired, Student's *t*-tests were utilized for comparing SUVR measurements. A 95% CI was set, correlating to *p*-values \<0.05 required for significant differences between stratified groups. Between 3 stratifications of groups, 7 ROIs, and two time points, 42 Student's *t*-tests for SUVR were conducted, and using six different HFs, 252 total Wilcoxon tests were performed. For a group of ROIs and HFs, we controlled False Discovery Rate (FDR) at 0.05 level to deal with multiple comparisons.

In addition to statistical testing, receiver operating characteristic (ROC) curves were generated to determine the discrimination performance of the selected regional HFs and the SUVR values. Groups were stratified as described previously except that data from HFs and SUVR from baseline and 24-month follow-up were combined. The Area under the Curve (AUC) was used to quantitatively characterize each generated ROC curve.

Results
=======

Gray Level Co-occurrence matrices were generated for slices through predefined brain structures. Shown in [Figure 2](#f2-cia-12-2077){ref-type="fig"} are a representative slice of the discretized PCC from a normal and MCI subject used in the GLCM creation. Qualitatively, the PCC of the normal subject has a lower intensity than the PCC of the MCI. Accompanying each PCC slice are their GLCMs, averaged over our distance and direction range. In the representative case shown, we observe a greater degree of clustering in the normal GLCM versus the MCI GLCM, which exhibits a larger spread along its diagonal. Comparing the GLCM of normal and MCI subjects, we observed GLCMs with more occurrences at greater discretized intensities for MCI subjects.

Results from the Student's *t*- and Wilcoxon tests are displayed in [Tables 2](#t2-cia-12-2077){ref-type="table"}[](#t3-cia-12-2077){ref-type="table"}--[4](#t4-cia-12-2077){ref-type="table"} with boxplots comparing the HFs and SUVRs for the precuneus and PCC shown in [Figure 3](#f3-cia-12-2077){ref-type="fig"}. Overall, the HFs were capable of distinguishing groups at baseline and follow-up (at FDR =0.05 level) in particular regions. In total, 124 out of 252 Wilcoxon tests showed significant differences between stratified groups. The majority of these differences were exhibited in the subjects grouped by diagnosis at both baseline and 24-month follow-up. Specifically, Energy and Entropy were capable of distinguishing normal and MCI subjects in all brain regions at baseline and nearly all structures at follow-up (except for Energy in the LFL). For the APOE and ADAS-Cog stratified groups, fewer HFs were capable of distinguishing groups in specific brain regions. However, we found significant differences in these groups using Energy and Entropy in the PCC at baseline for ADAS-Cog in [Table 4](#t4-cia-12-2077){ref-type="table"} and follow-up for APOE in [Table 3](#t3-cia-12-2077){ref-type="table"}. Conversely, we observed no significant differences between all groups and ROIs at baseline or follow-up utilizing SUVR (0 of 42 performed tests).

ROC curves for the PCC and all AUC values are displayed in [Figure 4](#f4-cia-12-2077){ref-type="fig"}. The ROC AUCs are presented in [Table 5](#t5-cia-12-2077){ref-type="table"}, respectively. From [Figure 4A and C](#f4-cia-12-2077){ref-type="fig"}, we observed that Energy and Entropy offered the best performance to distinguish Normal versus MCI and ADAS-Cog negative versus ADAS-Cog positive groups. Conversely, SUVR and Entropy provided the best methods APOE-ε4 carriers versus non-carriers, as viewed in [Figure 4B](#f4-cia-12-2077){ref-type="fig"}, while Energy exhibited lower performance. From [Table 5](#t5-cia-12-2077){ref-type="table"}, we observed that several metrics were best for differentiating stratified groups. For the classifications based on clinical diagnosis and ADAS-Cog, Energy gave the best performance across all ROIs. the APOE-ε4 classification, Entropy performed the followed by SUVR and Dissimilarity as secondary metrics. Homogeneity ranked as the second best metric for the ADAS-Cog classification. Several other HFs exhibited AUC values close to 0.5, considerably not better than random guessing.

Discussion
==========

The objective of this study was to determine whether higher-order texture-based features derived from the GLCMs of \[^18^F\]-Florbetapir-PET images can identify statistically significant differences between subject groups without using a reference region for PET intensity normalization. Subjects were classified with respect to their clinical diagnosis, APOE-ε4 status, and ADAS-Cog score to make a comparison between Haralick texture features and the conventional SUVR approach.

The results of the statistical and diagnostic testing revealed that the HFs Energy and Entropy provide the best descriptor for distinguishing normal and MCI subjects across all brain structures of interest. There was statistically significant separation in Energy and Entropy between the normal and MCI subject populations in the majority of ROIs at baseline and 24-month follow-up. Energy and Entropy also offered the largest AUC values for accurately classifying subjects with respect to their clinical diagnosis (Normal versus MCI) or ADAS-Cog status (negative versus positive).

An interesting consequence observed from the results is the apparent disconnect between the statistical testing and ROC diagnostic performance. Results from the Student's *t*-tests determined that no significant differences were exhibited in SUVR for each stratified group in all ROIs. However, ROC curve analysis verified SUVR's capability to distinguish populations, specifically in the RTL. This diagnostic capability also extended to all brain regions for the APOE stratified group, with AUC values \>0.5, including the PCC, as seen in [Figure 4B](#f4-cia-12-2077){ref-type="fig"}. Recall that AUC can be interpreted as diagnosis accuracy as a percentage, where 0.5 represents 50% accuracy. Even though SUVR appears to be a sensitive metric for differentiating APOE populations, other texture features perform better with respect to the two other classification schemes.

HFs are abstract mathematical models that are used in many different applications. The innovative aspect of this study was to utilize these features for characterizing abnormal Aβ pathology from non-normalized florbetapir-PET images. From early post-mortem studies,[@b22-cia-12-2077] we know that over time the progressive Aβ accumulation encompasses a greater extent of cerebral cortical laminae. The same pattern of spatial spread is observed in Aβ-PET images.[@b23-cia-12-2077] These spatial changes can affect the local disorder, homogeneity, variation, and similarity of pixel intensities, which can be captured by HFs.

One of the limitations of this study is the small sample size, which limits the interpretation regarding diagnostic capabilities. However, the overall objective was to compare a new image analysis method with a standard technique. The outcomes of our study indicate that, for the same sample size, our new method shows more significant group differences than the SUVR values.

Conclusion
==========

In this pilot study, a novel texture-based approach to assessing diagnostic statuses of amyloid burden was evaluated. We demonstrated that HFs, specifically Energy, could be used to effectively classify patients with respect to their clinical diagnosis, APOE-ε4 status, and ADAS-Cog score, compared to SUVR. These results suggest that this technique has potentials to improve subject stratification in AD drug trials and help evaluate the disease progression and treatment effects longitudinally without the potential biases associated with the reference region normalization.
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![(**A**) The coordinates of 34 offsets with respect to (0, 0). These 34 different offsets were used to calculate 33 gray level co-occurrence matrices (GLCMs) for each axial slice of a regional positron emission tomography image. (**B**) A representative image where two sample voxel pairs for two different offsets, (0°, distance =1) and (135°, distance =1) are highlighted. The discrete image voxel values are 1, 2, 3, and 4. (**C**) GLCM of image (**B**) for (0°, distance =1). The x and y axis represent the ordered (from low to high) voxel values of image (**B**). The z values represent the number of occurrences of a specific pair of voxel values (eg, 3 and 2) for a given offset (0°, distance =1). (**D**) GLCM of image (**B**) for (135°, distance =1). The x and y axis represent the ordered (from low to high) voxel values of image (**B**). The z values represent the number of occurrences of a specific pair of voxel values (eg, 3 and 2) for a given offset (135°, distance =1).](cia-12-2077Fig1){#f1-cia-12-2077}

![Representative axial slices of Aβ-PET images in PCC from (**A**) single normal subject and (**B**) single MCI subject. Accompanying each PCC slice are their gray level co-occurrence matrices, normal (**C**) and MCI (**D**), averaged over a range of distances and directions.\
**Abbreviations:** MCI, mild cognitive impairment; PCC, posterior cingulate cortex; PET, positron emission tomography.](cia-12-2077Fig2){#f2-cia-12-2077}

![Boxplots of measured metrics for the combined precuneus and posterior cingulate cortex.\
**Notes:** (**A**) Contrast, (**B**) Correlation, (**C**) Dissimilarity, (**D**) Energy, (**E**) Entropy, (**F**) Homogeneity, (**G**) SUVR. Metrics with statistically significant differences are shown with corresponding *p*-values \<0.05.\
**Abbreviations:** MCI, mild cognitive impairment; SUVR, standardized uptake value ratio.](cia-12-2077Fig3){#f3-cia-12-2077}

![Representative ROC curves characterizing the diagnostic capability of HFs and SUVR measurements within the combined precuneus and posterior cingulate cortex.\
**Notes:** ROC curves for the groups stratified by (**A**) Alzheimer's disease neuroimaging initiative clinical diagnosis (N versus mild cognitive impairment), (**B**) APOE status, and (**C**) ADAS-Cog status. The HF Energy exhibits the greatest capability to distinguish subjects in the Alzheimer's disease diagnosis and ADAS-Cog stratified groups.\
**Abbreviations:** ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive subscale; HFs, Haralick features; ROC, receiver operating characteristic; SUVR, standardized uptake value ratio.](cia-12-2077Fig4){#f4-cia-12-2077}

###### 

Demographic Alzheimer's disease neuroimaging initiative subject data for this study

  Stratification         Normal     MCI        APOE non carrier   APOE carrier   ADAS-Cog negative   ADAS-Cog positive
  ---------------------- ---------- ---------- ------------------ -------------- ------------------- -------------------
  Number of subjects     15         15         14                 16             16                  14
  Female (male)          8 (7)      5 (10)     8 (6)              5 (11)         6 (10)              7 (7)
  Age (mean ± SD)        74.7±4.3   73.6±8.7   77.4±7.4           74.6±6.7       74.7±4.9            77.2±9.0
  ADAS-Cog (mean ± SD)   6.7±4.2    12.7±7.7   9.9±8.1            9.6±5.7        5.4±2.3             14.6±7.0

**Abbreviations:** ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive subscale; MCI, mild cognitive impairment.

###### 

FDR-adjusted *p*-values of HFs and SUVR group difference (N, MCI) at baseline and follow-up

  Feature         Normal vs MCI at baseline   Normal vs MCI at follow-up                                                                                                      
  --------------- --------------------------- ---------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Contrast        0.0506                      0.0163                       0.0118   0.0245   0.0049   0.1576   0.4649   0.3589   0.0391   0.0871   0.0259   0.0044   0.8188   0.981
  Correlation     0.0353                      0.0506                       0.0317   0.0689   0.0868   0.0049   0.0118   0.0044   0.0608   0.1917   0.8983   0.1141   0.174    0.1118
  Dissimilarity   0.0749                      0.0184                       0.0245   0.0298   0.0049   0.2251   0.3836   0.3907   0.0397   0.0572   0.0229   0.0044   0.6403   0.7915
  Energy          0.0049                      0.0406                       0.0082   0.0049   0.0049   0.0381   0.0381   0.0044   0.0259   0.0082   0.0044   0.0044   0.3589   0.0381
  Entropy         0.0049                      0.0698                       0.014    0.0049   0.0049   0.014    0.0082   0.0044   0.0423   0.0151   0.0044   0.0044   0.0622   0.0082
  Homogeneity     0.3099                      0.0245                       0.0385   0.0245   0.0049   0.1987   0.1566   0.5098   0.0533   0.0392   0.0175   0.0044   0.168    0.315
  SUVR            0.385                       0.6054                       0.6338   0.74     0.74     0.7319   0.5245   0.2688   0.4134   0.4163   0.6292   0.5994   0.4709   0.3055

**Note:** Controlling for FDR at 0.05, the adjusted *p*-values smaller than 0.05 (blue color) indicate significant group differences.

**Abbreviations:** FDR, false discovery rate; HFs, Haralick features; LFL, left frontal lobe; LPL, left parietal lobe; LTL, left temporal lobe; MCI, mild cognitive impairment; PCC, posterior cingulate cortex; RFL, right frontal lobe; RPL, right parietal lobe; RTL, right temporal lobe; SUVR, standardized uptake value ratio.

###### 

FDR-adjusted *p*-values of HFs and SUVR group difference (APOE-negative, APOE-positive) at baseline and follow-up

  Feature         APOE-E4 carriers vs non-carriers at baseline   APOE-E4 carriers vs non-carriers at follow-up                                                                                                      
  --------------- ---------------------------------------------- ----------------------------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Contrast        0.3185                                         0.5641                                          0.2646   0.5488   0.5641   0.5042   0.0926   0.28     0.385    0.0716   0.5278   0.2096   0.4883   0.968
  Correlation     0.0858                                         0.2321                                          0.1895   0.273    0.147    0.2321   0.3308   0.6995   0.5278   0.0098   0.2838   0.0098   0.0882   0.0612
  Dissimilarity   0.3185                                         0.5488                                          0.1895   0.4807   0.5673   0.4237   0.1029   0.1729   0.3524   0.0381   0.5278   0.1729   0.3739   0.9606
  Energy          0.0858                                         0.5641                                          0.3383   0.3185   0.2321   0.0327   0.022    0.0392   0.8501   0.5278   0.8929   0.2838   0.0098   0.0098
  Entropy         0.0858                                         0.5673                                          0.3383   0.3163   0.2321   0.049    0.022    0.049    0.8542   0.5278   0.8501   0.3018   0.0098   0.0122
  Homogeneity     0.4083                                         0.4805                                          0.049    0.3185   0.8014   0.3308   0.1069   0.0122   0.2254   0.0122   0.5814   0.0882   0.2254   0.6995
  SUVR            0.5837                                         0.4805                                          0.4083   0.918    0.7079   0.3379   0.1895   0.8501   0.6486   0.573    0.9606   0.8969   0.5278   0.2838

**Note:** Controlling for FDR at 0.05, the adjusted *p*-values smaller than 0.05 (blue color) indicate significant group differences.

**Abbreviations:** FDR, false discovery rate; HFs, Haralick features; LFL, left frontal lobe; LPL, left parietal lobe; LTL, left temporal lobe; PCC, posterior cingulate cortex; RFL, right frontal lobe; RPL, right parietal lobe; RTL, right temporal lobe; SUVR, standardized uptake value ratio.

###### 

FDR-adjusted *p*-values of HFs and SUVR group difference (ADAS-Cog-negative, ADAS-Cog-positive) at baseline and follow-up

  Feature         ADAS-Cog negative vs positive at baseline   ADAS-Cog negative vs positive at follow-up                                                                                                      
  --------------- ------------------------------------------- -------------------------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Contrast        0.1994                                      0.1994                                       0.0754   0.1315   0.0686   0.1315   0.1994   0.2554   0.3369   0.294    0.1102   0.091    0.091    0.127
  Correlation     0.6136                                      0.7809                                       0.4923   0.3127   0.3416   0.686    0.3127   0.091    0.4477   0.5484   0.2292   0.1102   0.1903   0.1102
  Dissimilarity   0.2282                                      0.1994                                       0.0754   0.1315   0.07     0.1446   0.1994   0.343    0.3237   0.2554   0.1102   0.091    0.091    0.1823
  Energy          0.049                                       0.446                                        0.1994   0.1315   0.0754   0.049    0.2282   0.1102   0.2292   0.1449   0.1102   0.1102   0.1102   0.2292
  Entropy         0.049                                       0.4139                                       0.1994   0.1315   0.0754   0.049    0.1994   0.1102   0.2292   0.1213   0.1102   0.1102   0.091    0.1674
  Homogeneity     0.3416                                      0.1994                                       0.0754   0.0754   0.07     0.1315   0.2282   0.6064   0.3205   0.2292   0.1102   0.091    0.1102   0.3205
  SUVR            0.3668                                      0.4957                                       0.4923   0.4923   0.6032   0.818    0.5891   0.3205   0.357    0.3292   0.3829   0.4676   0.666    0.453

**Note:** Controlling for FDR at 0.05, the adjusted *p*-values smaller than 0.05 (blue color) indicate significant group differences.

**Abbreviations:** ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive subscale; FDR, false discovery rate; HFs, Haralick features; LFL, left frontal lobe; LPL, left parietal lobe; LTL, left temporal lobe; PCC, posterior cingulate cortex; RFL, right frontal lobe; RPL, right parietal lobe; RTL, right temporal lobe; SUVR, standardized uptake value ratio.

###### 

AUC values derived from ROC curve analysis

  Feature         Normal vs MCI   APOE carriers vs non-carriers   ADAS-Cog negative vs positive                                                                                                                                           
  --------------- --------------- ------------------------------- ------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Contrast        0.577           0.626                           0.61                            0.621   0.664   0.536   0.52    0.569   0.542   0.595   0.538   0.558   0.548   0.555   0.57    0.565   0.589   0.596   0.624   0.602   0.583
  Correlation     0.644           0.603                           0.595                           0.55    0.589   0.613   0.598   0.547   0.516   0.631   0.573   0.629   0.591   0.589   0.547   0.514   0.504   0.56    0.575   0.546   0.584
  Dissimilarity   0.569           0.623                           0.612                           0.621   0.667   0.546   0.533   0.578   0.546   0.609   0.541   0.559   0.556   0.557   0.56    0.567   0.591   0.599   0.621   0.601   0.576
  Energy          0.694           0.615                           0.647                           0.69    0.675   0.579   0.613   0.622   0.524   0.55    0.539   0.576   0.667   0.665   0.622   0.557   0.583   0.601   0.601   0.618   0.57
  Entropy         0.695           0.603                           0.639                           0.686   0.671   0.619   0.644   0.621   0.523   0.55    0.544   0.575   0.645   0.657   0.619   0.558   0.587   0.596   0.604   0.636   0.578
  Homogeneity     0.547           0.616                           0.614                           0.624   0.661   0.565   0.558   0.594   0.565   0.639   0.549   0.56    0.571   0.568   0.542   0.565   0.591   0.605   0.626   0.601   0.562
  SUVR            0.578           0.564                           0.548                           0.53    0.51    0.562   0.601   0.608   0.584   0.568   0.507   0.522   0.57    0.624   0.513   0.5     0.517   0.595   0.575   0.502   0.537

**Note:** Blue highlight indicates AUCs above 0.6.

**Abbreviations:** ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive subscale; AUC, area under the curve; LFL, left frontal lobes; LPL, left parietal lobe; LTL, left temporal lobe; MCI, mild cognitive impairment; PCC, posterior cingulate cortex; RFL, right frontal lobes; ROC, receiver operating characteristic; RPL, right parietal lobe; RTL, right temporal lobe; SUVR, standardized uptake value ratio.
